What type of study is this?

This is a In Vitro Study study.

Multi-Method Investigation of Icariin's Effects on Diabetic Cognitive Impairment: From Network Prediction to Experimental Confirmation

View Full Paper

Ask AI

Bookmark

Authors

Network pharmacology reveals icariin modulates MAPK signaling in diabetic cognitive impairment, suggesting therapeutic potential.

Icariin demonstrates protective effects against high glucose-induced damage in HT22 cells, indicating potential for diabetic cognitive impairment.
Network pharmacology suggests icariin modulates the MAPK pathway and has anti-inflammatory effects, highlighting its therapeutic relevance.
Molecular docking and in vitro studies confirm that icariin suppresses pro-inflammatory cytokine release and regulates MAPK signaling.
Further research is needed to assess icariin's effects in diabetic animal models and its interaction with antidiabetic drugs.

Jiao et al. (2025) studied this question.

View Full Paper

Ask AI

Bookmark